Tag: Umifenovir
Glenmark introduces higher strength (400 mg) of FabiFlu
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it would introduce a 400 mg version of oral antiviral FabiFlu to treat mild...
Glenmark reduces price of oral antiviral FabiFlu by 27 % to...
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely...
Glenmark gets nod from DCGI for Favipiravir launch
In a landmark development for Covid-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced the launch of antiviral drug Favipiravir...
Umifenovir gets DCGI approval for Phase III clinical trial
CSIR constituent lab CSIR-Central Drug Research Institute (CDRI) Lucknow has received permission for carrying out Phase III randomized, Double-blind, Placebo-controlled trial of efficacy, safety,...
Glenmark to commence new Phase 3 clinical trial on a combination...
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced a new randomized, open-label study to test the combined efficacy of two antiviral drugs...